• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Chest Pain in an Adult Male With an Ominous ECG

Article

Can you discern the anomaly in this patient's ECG? What clue(s) does it provide to the underlying pathology?

Figure 1.

Figure 2.

A 47-year-old man with no previous medical history called 911 complaining of chest pain; EMS treated the patient with aspirin and sublingual nitrates and obtained an ECG (Figure1) at 9:50 am. He was transported emergently to the emergency department (ED) with chest pain described as an aching sensation. The pain was associated with nausea, dyspnea, and diaphoresis and had begun intermittently approximately 5 hours before the 911 call that morning. On ED arrival, the patient was ill-appearing with significant diaphoresis. The examination was otherwise unremarkable. An ECG (Figure 2) was obtained at 10:03 am while management continued.

The high-risk findings noted on the ECG in Figure 2 include which of the following:   

A. ST-segment elevation in lead aVr.

B. Prominent T waves in the right to mid-precordial leads.

C. ST-segment depression in the right to mid-precordial leads.

D. All of the above.

Please leave your answer below then click here for answer and discussion.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
© 2024 MJH Life Sciences

All rights reserved.